Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Income from Continuing Operations (2016 - 2025)

Adma Biologics (ADMA) has disclosed Income from Continuing Operations for 13 consecutive years, with 60400000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income from Continuing Operations fell 46.02% year-over-year to 60400000.0, compared with a TTM value of 157950000.0 through Dec 2025, down 20.1%, and an annual FY2025 reading of 157950000.0, down 20.1% over the prior year.
  • Income from Continuing Operations was 60400000.0 for Q4 2025 at Adma Biologics, up from 36427000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 111896000.0 in Q4 2024 and bottomed at 18821986.0 in Q2 2021.
  • Average Income from Continuing Operations over 5 years is 11281400.0, with a median of 1903000.0 recorded in 2023.
  • The sharpest move saw Income from Continuing Operations soared 1299.96% in 2024, then crashed 46.02% in 2025.
  • Year by year, Income from Continuing Operations stood at 16504574.0 in 2021, then rose by 28.55% to 11792616.0 in 2022, then skyrocketed by 189.84% to 10595000.0 in 2023, then skyrocketed by 956.12% to 111896000.0 in 2024, then plummeted by 46.02% to 60400000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for ADMA at 60400000.0 in Q4 2025, 36427000.0 in Q3 2025, and 34219000.0 in Q2 2025.